Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Construction will begin this year with the new capacity anticipated by 2025
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated